Canada Scores Low Grade on Drug Regulation

International Pharmaceutical Regulatory Monitor
A A
Health Canada routinely misses statutory deadlines for reviewing generic drugs, over-the-counter (OTC) formulations requiring clinical review and postmarket change submissions, the auditor general of Canada says.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00